Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...
Sabra Health Care REIT offers a 6.4% yield, strong SHOP growth, safe leverage, no debt until 2027, and long-term tailwinds. See why SBRA stock is a buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback